Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Glioblastoma 2Carcinoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Perivascular Epithelioid Cell Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Mucositis 1Mouth Neoplasms 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Histiocytoma, Angiomatoid Fibrous 1Head and Neck Neoplasms 1Granuloma, Plasma Cell 1Gliosarcoma 1Fibrosarcoma 1

Interventions

Cyclophosphamide 10Etoposide 6Doxorubicin 6Cytarabine 6Prednisone 5Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Methotrexate 4gamma-Globulins 3Rituximab 3Radiotherapy 3Filgrastim 3Ciprofloxacin 3pegaspargase 2nelarabine 2etoposide phosphate 2calaspargase pegol 2Triptorelin Pamoate 2Thioguanine 2Prednisolone 2Methylprednisolone 2Mercaptopurine 2Melphalan 2Magnetic Resonance Spectroscopy 2Immunoglobulins, Intravenous 2Dexamethasone 2Daunorubicin 2Cyclosporine 2Calcium Dobesilate 2Bortezomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma × Radiation × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡